Author:
Ignatova G L,Blinova E V,Antonov V N,Grebneva I V
Abstract
Aim. The article presents data on the evaluation of the clinical efficacy of using a conjugated pneumococcal vaccine in patients with COPD in combination with 2-type diabetes during a 3-year follow - up period. Materials and methods. The study included 309 patients with an isolated course of COPD and in combination with diabetes. The main parameters for evaluating the effectiveness were: the dynamics of clinical symptoms - shortness of breath on the mMRC scale, CAT test, FEV1, the number of exacerbations, hospitalizations, the number of pneumonia, the state of carbohydrate metabolism (HbA1c) and the lipid profile. For vaccine prevention 13-valent conjugated pneumococcal vaccine Prevenar-13 was used. Results and conclusions. The use of PСV13 helps to reduce the severity of respiratory symptoms, reduce the number and duration of exacerbations of COPD, reduce the number of pneumonia. Both in isolated course of COPD and in combination with diabetes. Vaccination PCV13 in patients with comorbid course contributes to the compensation of carbohydrate metabolism and improve the lipid profile.
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice
Reference35 articles.
1. Global Initiative for Chronic Obstructive Lung Disease, GOLD, 2018. аvailable at: http://www.goldcopd.org
2. Ромашов Б.Б., Полякова Н.В. Особенности патогенеза, клиники и лечения сочетания хронической обструктивной болезни легких и сахарного диабета. Молодой ученый. 2015;13:310-4.
3. Les comorbidités dans la BPCO : un nouvel enjeu en pratique clinique
4. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: клинические рекомендации. Вып. 8. И.И. Дедов, М.В. Шестакова, А.Ю. Майоров, ред. М., 2017.
5. Diabetes, Glycemic Control, and Risk of Hospitalization With Pneumonia
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献